X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

New ‘peptoids’ show promise in resistant prostate cancer

A new generation of anti-androgen drugs such as Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Zytiga have increased survival... Read More

Sophiris Stops Additional Doses in Topsalysin Prostate Cancer Trial Following Patient Death

Sophiris Bio has halted additional doses in an open-label study of topsalysin in prostate cancer, as it investigates the death... Read More

Testing for 63 Gene Variants Identifies Elevated Risk for Prostate Cancer

A transatlantic team of scientists led by the London-based Institute of Cancer Research (ICR) has made a major step towards... Read More

Dendreon Eyes Real-World Data Boost for Lagging Prostate Cancer Med Provenge

Years after winning a hotly anticipated FDA approval for its cancer immunotherapy Provenge—and struggling to build sales of the prostate... Read More

Myriad Touts 10-Year Data for Prostate Cancer Screen

Myriad Genetics unveiled new data showing its prostate cancer diagnostic could accurately predict the 10-year risk of metastasis in men... Read More

Researchers Create Test to Predict Response to Xtandi, Zytiga

Researchers have created a $65 test designed to show which prostate cancer patients will respond to Pfizer’s Xtandi and Johnson... Read More

Newly Discovered Genetic Fngerprint for Prostate Cancer Promises to Personalize Treatment

Scientists at the University of Toronto have discovered a set of genetic mutations that they believe will help oncologists predict when... Read More